Back to top
more

DexCom (DXCM)

(Delayed Data from NSDQ)

$67.45 USD

67.45
20,837,305

-8.33 (-10.99%)

Updated Sep 19, 2025 03:59 PM ET

After-Market: $67.63 +0.18 (0.27%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (87 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay

by Zacks Equity Research

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Zacks Equity Research

OrthoPediatrics (KIDS) Introduces Unit for Non-Surgical Bracing

by Zacks Equity Research

OrthoPediatrics (KIDS) continues to diversify its non-surgical offerings with the introduction of the DF2 Brace.

Zacks Equity Research

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and a favorable liquidity structure.

Zacks Equity Research

Tandem Diabetes (TNDM) Launches Dexcom G7 Integrated t:slim X2

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.

Zacks Equity Research

Is DexCom (DXCM) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

DexCom (DXCM) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

3 Reasons to Retain AMN Healthcare (AMN) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.

Zacks Equity Research

Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail

by Zacks Equity Research

Omnicell (OMCL) accelerates a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service and Central Pharmacy Dispensing Services.

Zacks Equity Research

HealthEquity (HQY) Q3 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in the majority of its segments, in the third quarter of fiscal 2024.

Zacks Equity Research

Neogen (NEOG) to Offer Biosecurity Products With New Pact

by Zacks Equity Research

Neogen will be able to highlight its biosecurity and horse health products, like the COMPANION range of cleansers and disinfection solutions, through the latest collaboration.

Zacks Equity Research

Here's Why You Should Retain Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) on global expansion and strategic alliance.

Zacks Equity Research

West Pharmaceutical's (WST) New Launch to Expand Portfolio

by Zacks Equity Research

West Pharmaceutical's (WST) latest addition to its portfolio is likely to address the critical need for more drug preparation and delivery options at the point of care.

Zacks Equity Research

Why You Should Retain UnitedHealth Group (UNH) Stock Now

by Zacks Equity Research

Growing membership, expanding government business, strategic acquisitions, improving operating margin and solid growth outlook poise UnitedHealth Group (UNH) well for growth.

Zacks Equity Research

Integra Gains From New Product Launches, Mounting Costs Ail

by Zacks Equity Research

Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.

Zacks Equity Research

Boston Scientific (BSX) Gains From Global Expansion, FX Woe Ails

by Zacks Equity Research

Boston Scientific's (BSX) Endoscopy business within MedSurg benefits from strong worldwide demand for its broad range of GI and pulmonary treatment options.

Zacks Equity Research

Henry Schein's (HSIC) Zahn Dental and Myerson Enter New Deal

by Zacks Equity Research

Henry Schein's (HSIC) dental laboratory business, Zahn Dental, is set to exclusively distribute Myerson's New Trusana 3D Premium Denture System.

Zacks Equity Research

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.

Zacks Equity Research

Community Health (CYH) Sells Three Florida Facilities for $294M

by Zacks Equity Research

Community Health (CYH) divests three hospitals in Florida to Tampa General Hospital, substantiating its endeavor to intensify its focus on high-growth business areas.

Zacks Equity Research

Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue?

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments.

Zacks Equity Research

Thermo Fisher (TMO) Advances Health Equity via New Partnership

by Zacks Equity Research

Thermo Fisher (TMO) announces a collaboration with Project HOPE to improve health outcomes by enabling expanded access to HIV testing and support services in Nigeria.

Zacks Equity Research

BiomX (PHGE) Reports Positive Pulmonary Infection Treatment Data

by Zacks Equity Research

BiomX's (PHGE) BX004 showcases an impressive 14% conversion to a negative P. aeruginosa sputum culture at the end of treatment.

Zacks Equity Research

Nevro (NVRO) Up 15.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Neogen (NEOG) Unveils New Assay for Walnut Allergens Detection

by Zacks Equity Research

Neogen's (NEOG) Veratox VIP for Walnut allergy test displays robust performance across sample types while keeping the Veratox product line's simple testing approach.

Zacks Equity Research

CVS Health's (CVS) Digital Focus Aids Growth, Macro Issues Ail

by Zacks Equity Research

CVS Health's (CVS) Health Care Benefits segment demonstrates value to consumers and clients by successfully managing drug cost trends and bringing innovative clinical solutions to the market.

Zacks Equity Research

Philips (PHG) Adds Smart Fit Coils to Boost Diagnostic Imaging

by Zacks Equity Research

Philips (PHG) launches three MR Smart Fit coils, namely TorsoCardiac 1.5T, 1.5T shoulder and Knee 3.0T, enhancing flexibility, reducing patient setup time and improving image quality resolution.

Zacks Equity Research

Walgreens (WBA) Launches Rx Savings Finder Digital Tool

by Zacks Equity Research

Walgreens (WBA) introduces Rx Savings Finder to help patients save on prescription medications.